Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC).

被引：0
作者：
Berghoff, A.
Bartsch, R.
Bago-Horvath, Z.
Dubsky, P. C.
Rudas, M.
Pluschnig, U.
Wiltschke, C.
Gnant, M.
Steger, G. G.
Zielinski, C.
机构：
[1] Med Univ Vienna, Div Oncol, Dept Med 1, Vienna, Austria
[2] Med Univ Vienna, Div Clin Oncol, Dept Med 1, Vienna, Austria
[3] Med Univ Vienna, Dept Pathol, Vienna, Austria
[4] Med Univ Vienna, Dept Surg, Vienna, Austria
[5] Med Univ Vienna, Vienna, Austria
[6] Med Univ Vienna, Ctr Comprehens Canc, Dept Surg, Vienna, Austria
[7] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
572
引用
收藏
页数：1
相关论文
共 50 条
[21]   A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer [J].
Munster, Pamela N. ;
Miller, Kathy ;
Krop, Ian E. ;
Dhindsa, Navreet ;
Reynolds, Joe ;
Geretti, Elena ;
Niyikiza, Clet ;
Nielsen, Ulrik ;
Hendriks, Bart ;
Wickham, Thomas J. ;
Moyo, Victor M. ;
LoRusso, Patricia .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[22]   Overall Survival for HER2-Positive Breast Cancer Patients in the HER2-Targeted Era: Evidence From a Population-Based Study [J].
Marczyk, Vicente Rodrigues ;
Rosa, Daniela Dornelles ;
Maia, Ana Luiza ;
Goemann, Iuri Martin .
CLINICAL BREAST CANCER, 2022, 22 (05) :418-423
[23]   Outcome of HER2-Positive (HER2+) Metastatic Breast Cancer Patients (MBC) Treated with Trastuzumab (T): An Institutional Based Review [J].
Guilhaume, M-N ;
Dieras, V ;
Fall, M. ;
Pierga, J-Y ;
Beuzeboc, P. ;
Cottu, P. H. ;
Simondi, C. ;
Courbard, M. ;
Mignot, L. ;
Livartowski, A. .
CANCER RESEARCH, 2009, 69 (24) :801S-801S
[24]   TNFα induces multiresistance to HER2-targeted TNFα induces multiresistance to HER2-targeted therapies in HER2-positive breast cancer [J].
Mercogliano, Maria F. ;
De Martino, Mara ;
Bruni, Sofia ;
Venturutti, Leandro ;
Rivas, Martin ;
Amasino, Matias ;
Proietti, Cecilia J. ;
Elizalde, Patricia V. ;
Schillaci, Roxana .
CANCER RESEARCH, 2017, 77
[25]   HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis [J].
Erickson, Anders W. ;
Ghodrati, Farinaz ;
Habbous, Steven ;
Jerzak, Katarzyna J. ;
Sahgal, Arjun ;
Ahluwalia, Manmeet S. ;
Das, Sunit .
NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
[26]   Shorter Overall Survival (OS) in HER2-positlve (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) ± chemotherapy (CT) and overexpressing HER3 by immunohistochemistry (IHC) [J].
Gori, S. ;
Sidoni, A. ;
Colozza, M. ;
Mameli, M. G. ;
Fenocchio, D. ;
Minenza, E. ;
Foglietta, J. ;
Stocchi, L. ;
De Angelis, V. ;
Crino, L. .
EJC SUPPLEMENTS, 2009, 7 (02) :287-287
[27]   Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer [J].
Michiels, S. ;
Pugliano, L. ;
Marguet, S. ;
Grun, D. ;
Barinoff, J. ;
Cameron, D. ;
Cobleigh, M. ;
Di Leo, A. ;
Johnston, S. ;
Gasparini, G. ;
Kaufman, B. ;
Marty, M. ;
Nekljudova, V. ;
Paluch-Shimon, S. ;
Penault-Llorca, F. ;
Slamon, D. ;
Vogel, C. ;
von Minckwitz, G. ;
Buyse, M. ;
Piccart, M. .
ANNALS OF ONCOLOGY, 2016, 27 (06) :1029-1034
[28]   A Phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer heavily pre-treated with HER2-targeted therapy [J].
Brufsky, Adam ;
Zulfiqar, Malik ;
Peguero, Julio ;
Lathrop, Kate ;
Bhat, Gajanan ;
Lebel, Francois .
CANCER RESEARCH, 2021, 81 (04)
[29]   registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR plus ) metastatic breast cancer (MBC) [J].
Tripathy, D. ;
Kaufman, P. ;
Brufsky, A. ;
Mayer, M. ;
Yood, M. ;
Wang, L. ;
Brammer, M. ;
Yardley, D. ;
Tan-Chiu, E. ;
Rugo, H. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[30]   Delayed initiation of HER2-targeted therapy (HER2Tx) is associated with a higher risk of relapse for early stage (ES) HER2-positive (HER2+) breast cancer (BrCa) [J].
Gullo, G. ;
Bose, R. ;
Walsh, N. ;
Maltese, M. ;
Fennelly, D. ;
Walshe, J. ;
Ballot, J. ;
Crown, J. .
ANNALS OF ONCOLOGY, 2016, 27
12345